Drug Trial Radar · NCT00316524
A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Mar 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
745
Actual
Start
Apr 2006
Primary completion
Feb 2007
Study completion Aug 2007
Sponsor
- Lead sponsor
- Bavarian NordicIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Apr 21, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the immune response after a single vaccination of pre-immune subjects compared to two vaccinations in naive subjects. In addition the study further investigates the cardiac safety profile of MVA-BN® in a healthy population compared to placebo.
Conditions
- Smallpox
Interventions
MVA-BN® (IMVAMUNE)Biological
1x 10E8\_TCID50
PlaceboBiological
Tris-Buffer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Seroconversion by ELISATime frame: 2 weeks following the last vaccination (Week 6 for Groups 1-3, Week 2 for Group 4)
- Number of Participants With ECG ChangesTime frame: within 2 weeks after each vaccination
- Number of Cardiac Adverse Events (Adverse Events of Special Interest [AESI])Time frame: within 32 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Harrison Clinical Research GmbH
Munich, Bavaria, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.